$2.20
Today
as of Jul 22, 16:47 ET
Last 30 days
Recent Press Releases & News
Oppenheimer Initiates Connect Biopharma at Outperform With $8 Price Target
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Canaccord Genuity Initiates Connect Biopharma at Buy With $6 Price Target
Overview
52-week range
$0.75
$3.82
47% of range
Avg surprise (last 3)
+1.7%
Avg reaction (last 2)
+4.5%
50% positive
Latest IV / EM
189%
EM ±43.2% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.34 | $-0.29 | -17.2% | -79.0% | +14.5% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.31 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.23 | $-0.22 | -4.5% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.19 | $-0.26 | +26.9% | — | -5.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.23 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.27 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.16 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.32 | -$0.23 | -39.1% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $169,000 | — | $16,000 | $48,000 | $0 | — | $1M | $24M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-20M | — | $-18M | $-13M | $-11M | — | $-14M | $14M |
| Net income | $-19M | — | $-17M | $-13M | $-10M | — | $-13M | $15M |
| EPS (diluted) | $-0.34 | — | $-0.31 | $-0.23 | $-0.19 | — | $-0.23 | $0.27 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $46M | $38M | $38M | $41M | $48M | $78M | — | — |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $55M | $51M | $63M | $78M | $88M | $97M | — | — |
| Total assets | $60M | $56M | $67M | $83M | $93M | $101M | — | — |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $17M | $14M | $12M | $11M | $10M | $9M | — | — |
| Total equity | $43M | $42M | $55M | $71M | $83M | $92M | $101M | $111M |